Ohad Gal-Mor | Microbiology | Best Researcher Award

Published on by Molecular Biologist

Prof. Dr. Ohad Gal-Mor | Microbiology | Best Researcher Award 

Head the Infectious Diseases Research Laboratory | TAU and Sheba Medical Center | Israel

Prof. Dr. Ohad Gal-Mor is a distinguished microbiologist and academic leader specializing in infectious diseases and bacterial pathogenesis. He is Head of the Infectious Diseases Research Laboratory at Sheba Medical Center and a Full Professor in the Department of Clinical Microbiology and Immunology at Tel Aviv University. His research has significantly advanced the understanding of Salmonella virulence, persistence, and host adaptation. He has also contributed to the study of antimicrobial resistance and bacterial evolution, bridging fundamental microbiology with global public health. In addition to his scientific achievements, Prof. Gal-Mor has held influential leadership positions, including Director of the Nehemia Rubin Program for Excellence in Biomedical Research and Chair of the Biomedical Academic Research Institute at Sheba Medical Center. Through his research, teaching, and mentorship, he has shaped the careers of many young scientists and continues to contribute to advancing knowledge in microbiology and infectious diseases worldwide.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Prof. Dr. Ohad Gal-Mor pursued his academic training at Tel Aviv University, where he developed a strong foundation in molecular microbiology and life sciences. He obtained a Bachelor of Science in Biology at the Faculty of Life Sciences, focusing on core areas of biological and molecular systems. Following this, he was accepted into a prestigious direct-track doctoral program, earning his Ph.D. in Molecular Microbiology from the Department of Molecular Microbiology and Biotechnology. His doctoral research was dedicated to exploring microbial genetics and the mechanisms of host-pathogen interactions, providing the groundwork for his later contributions to bacterial pathogenesis. This rigorous training prepared him for postdoctoral research in Canada, where he worked with world-leading scientists and refined his expertise in host-pathogen studies. His educational background reflects both scientific rigor and an interdisciplinary approach, equipping him with the tools to investigate complex questions of microbial evolution, infection biology, and molecular regulation.

Experience

Prof. Dr. Ohad Gal-Mor has an extensive record of academic and research leadership in microbiology. After earning his Ph.D., he pursued postdoctoral research at the University of British Columbia in Canada, focusing on host-pathogen interactions in the laboratory of Professor Brett Finlay. He then advanced to a Research Associate role at the same institution before returning to Israel, where he became Director of the Enterobacteriaceae National Center at the Ministry of Health. Since then, he has established and led the Infectious Diseases Research Laboratory at Sheba Medical Center, driving innovation in infectious disease research. At Tel Aviv University, he progressed from Senior Lecturer to Associate Professor and is now a Full Professor. He has served as Secretary of the Israel Society for Microbiology and Section Editor for the journal Virulence. His professional journey highlights an exceptional blend of academic scholarship, research leadership, and international collaboration.

Research Interests

Prof. Dr. Ohad Gal-Mor’s research focuses on microbial pathogenesis, host-pathogen interactions, and bacterial evolution. His studies primarily investigate Salmonella enterica, with particular emphasis on genetic diversity, antimicrobial resistance, and adaptation to host environments. He explores how horizontally acquired elements, plasmids, and regulatory pathways contribute to virulence and persistence in both human and animal hosts. By integrating molecular biology, microbiology, and genomics, his group uncovers mechanisms that allow bacteria to survive within hosts, evade immune responses, and adapt to different ecological niches. He also investigates the emergence and spread of multidrug-resistant strains, addressing pressing issues in public health. His use of genomic sequencing, transcriptomics, and advanced infection models ensures that his research remains at the forefront of modern microbiology. Ultimately, his work aims to inform the development of novel antimicrobial strategies, vaccines, and prevention approaches, advancing both fundamental science and translational medicine.

Awards and Recognition

Prof. Dr. Ohad Gal-Mor has received recognition for his research excellence and leadership in the field of microbiology. His publication in PLoS Pathogens was highlighted as the Featured Image of the Month and selected as Paper of the Month by the German Society of Hygiene and Microbiology, showcasing his international impact. He has served in leadership roles such as Secretary of the Israel Society for Microbiology and Director of the Nehemia Rubin Program for Excellence in Biomedical Research at Sheba Medical Center, reflecting his dedication to advancing both science and education. His appointment as Chair of the Biomedical Academic Research Institute demonstrates the trust placed in his leadership within Israel’s largest medical center. These honors highlight his contributions not only as a researcher but also as a mentor and leader, recognized nationally and internationally for advancing the study of bacterial pathogenesis and infectious diseases.

Top Noted Publications

Prof. Dr. Ohad Gal-Mor has published extensively in leading international journals, making significant contributions to bacterial pathogenesis and antimicrobial resistance research. Selected publications include:

Title: The transcriptional regulation of the horizontally acquired iron uptake system, yersiniabactin and its contribution to oxidative stress tolerance and pathogenicity of globally emerging salmonella strains.
Journal: Gut Microbes
Year: 2024

Title: Persistent Salmonella infections in humans are associated with mutations in the BarA/SirA regulatory pathway.
Journal: Cell Host & Microbe
Year: 2024

Title: A new Salmonella enterica serovar that was isolated from a wild sparrow presents a distinct genetic, metabolic and virulence profile.
Journal: Microbes and Infection
Year: 2024

Title: The emergence of a multidrug resistant Salmonella Muenchen in Israel is associated with horizontal acquisition of the epidemic pESI plasmid.
Journal: Clinical Microbiology and Infection
Year: 2022

Title: Intracellular Salmonella Paratyphi A is motile and differs in the expression of flagella-chemotaxis, SPI-1 and carbon utilization pathways in comparison to intracellular S. Typhimurium.
Journal: PLoS Pathogens
Year: 2022

Title: The ancestral stringent response potentiator, DksA has been adapted throughout Salmonella evolution to orchestrate the expression of metabolic, motility, and virulence pathways.
Journal: Gut Microbes
Year: 2022

Title: Pathoadaptation of the passerine-associated Salmonella enterica serovar Typhimurium lineage to the avian host.
Journal: PLoS Pathogens
Year: 2021

Title: Emergence of new variants of antibiotic resistance genomic islands among multidrug-resistant Salmonella enterica in poultry.
Journal: Environmental Microbiology
Year: 2020

Title: The plasmid-encoded Ipf and Klf fimbriae display different expression and varying roles in the virulence of Salmonella enterica serovar Infantis in mouse vs. avian hosts.
Journal: PLoS Pathogens
Year: 2017

Conclusion

Prof. Dr. Ohad Gal-Mor stands out as a highly suitable nominee for the Best Researcher Award. His work addresses critical challenges in global health, particularly the rise of antibiotic resistance and the evolution of bacterial pathogens, issues of major concern for both science and society. His scientific rigor, combined with international recognition and leadership, justifies his candidacy as an exemplary researcher whose contributions have advanced the frontiers of microbiology and infectious disease research.

Jorge Castro | Nonclinical Toxicology | Best Researcher Award

Published on by Molecular Biologist

Dr. Jorge Castro | Nonclinical Toxicology | Best Researcher Award 

Head of Preclinical Research | Center for Genetic Engineering and Biotechnology | Cuba

Dr. Jorge Castro is a distinguished Doctor in Veterinary Medicine and Senior Researcher with expertise in animal physiology, health sciences, and biotechnology. He has made significant contributions to biomedical research, preclinical studies, and vaccine development. Holding advanced scientific degrees including a Master in Animal Physiology and a Ph.D. in Health Sciences, he has established himself as a leader in preclinical drug evaluation, immunology, and laboratory animal sciences. His career is strengthened by professional training in over forty specialized courses, covering areas such as toxicology, biosafety, molecular biology, and regulatory practices. As a professor and lecturer, he has shared his knowledge internationally, shaping the professional development of young researchers in biomedical sciences and laboratory animal welfare. His scientific work emphasizes innovation, ethical practices, and translational impact, positioning him as a highly respected figure in veterinary medicine and biotechnology at the global level.

Professional Profile

Scopus

Education

Dr. Jorge Castro holds a Doctorate in Veterinary Medicine, which provided him with a foundation in animal health and biomedical sciences. He pursued advanced studies, earning a Master of Science in Animal Physiology, focusing on complex biological mechanisms in animal systems. He further enhanced his expertise by completing a Doctorate in Health Sciences, specializing in preclinical drug development, immunology, and disease modeling. In addition to formal academic qualifications, he has undertaken extensive professional training in molecular biology, toxicology, biosafety, preclinical practices, immunotoxicology, and the use of non-human primates in biomedical research. He has also completed multiple workshops and certifications on experimental models, research methodology, and regulatory standards. This blend of advanced academic preparation and continuous training has positioned him as a recognized authority in preclinical research and biomedical innovation.

Experience

Dr. Jorge Castro has extensive experience as a Senior Researcher and First-Level Technologist, contributing to biomedical research, vaccine development, and preclinical evaluation. His work has included studies with non-human primate models in the fields of dengue and hepatitis, as well as the development of therapeutic cancer vaccines. He has served as a professor, lecturer, and invited speaker at numerous international congresses, workshops, and training programs, where he has delivered courses on laboratory animal welfare, ethics in experimentation, molecular biology, toxicology, and immunology. His professional career also demonstrates leadership in project management, strategic planning, and regulatory compliance. By combining research, teaching, and regulatory expertise, he has played a pivotal role in strengthening the integration of scientific innovation with practical biomedical solutions. His contributions extend beyond laboratory research, impacting both the scientific community and public health systems.

Research Interest

Dr. Castro’s research interests include biomedical sciences, animal physiology, and preclinical drug development. He has a particular focus on the use of animal models, including non-human primates and rodents, for studying viral infections, vaccine development, and cancer immunotherapy. His work has contributed significantly to dengue virus research, immunological evaluations, and recombinant vaccine formulations. He has also contributed to innovative research on hepatitis C, vascular endothelial growth factor (VEGF)-based therapeutic vaccines, and nanotechnology-based approaches to drug delivery. In addition, he has conducted studies in toxicology, immunotoxicology, and experimental physiology, always seeking to improve the translational relevance of preclinical findings to human medicine. His commitment to ethical laboratory animal use and adherence to regulatory frameworks reflects his focus on advancing scientific innovation while maintaining the highest standards of animal welfare and research integrity.

Awards

Dr. Jorge Castro  has been honored with distinctions such as Senior Researcher and First-Level Technologist, recognizing his outstanding contributions to biomedical sciences and animal health. His achievements are reflected in his international recognition as a professor, lecturer, and invited speaker at major congresses and scientific workshops, including international forums on immunopharmacology, agrobiotechnology, preclinical research, and vaccine development. His contributions to laboratory animal welfare, biosafety, and vaccine innovation have earned him wide respect in both academic and applied research communities. Beyond formal awards, his professional appointments, advisory roles, and invited lectures underscore the scientific community’s trust in his expertise. These recognitions highlight his ability to translate complex scientific knowledge into impactful biomedical solutions, strengthening global standards in preclinical research and innovation.

Top Noted Publications

Dr. Jorge Castro has authored numerous peer-reviewed publications in high-impact international journals, covering areas such as dengue virus infection models, vaccine development, and cancer immunotherapy. His research has been published in journals including Clinical Vaccine Immunology, Vaccine, Antiviral Research, Biotechnology Applied Biochemistry, and International Journal of Infectious Diseases. He has collaborated extensively with national and international scientists, advancing knowledge on heterologous prime-boost vaccine strategies, immunogenicity studies in non-human primates, and VEGF-based therapeutic vaccines. His contributions demonstrate a strong focus on translational science, ensuring that experimental findings provide practical biomedical applications. His publications are frequently cited by other researchers, reinforcing their scientific relevance. Through his work, he has positioned himself as an authority in vaccine immunology, preclinical testing, and biomedical innovation.

Title: Primary and Secondary infections by Asian and American genotypes of Dengue 2 Virus in Macaca fascicularis monkeys
Journal: Clinical Vaccine Immunology

Title: Immunization with a recombinant fowl pox virus expressing a hepatitis C virus Core-E1 polyprotein variant protects mice and monkeys
Journal: Biotechnology Applied Biochemistry

Title: Immunological evaluation in nonhuman primates of formulations based on chimeric dengue proteins
Journal: Vaccine

Title: Viremia and antibody response in green monkeys infected with dengue virus type 2
Journal: Microbiology and Immunology

Title: Immunogenicity and protective efficacy of a recombinant dengue protein in non-human primates
Journal: Antiviral Research

Title: Heterologous prime-boost strategy in nonhuman primates with dengue virus and recombinant protein
Journal: Infectious Diseases

Title: Immunogenicity and safety of a VEGF-based cancer therapeutic vaccine in animals
Journal: Vaccine

Title: Ratio of HCV structural antigens in protein-based vaccine formulations and immune response
Journal: Biotechnology Applied Biochemistry

Title: The chimeric protein domain III–capsid of Dengue Virus serotype 2 boosts neutralizing antibodies in primates
Journal: Clinical Vaccine Immunology

Title: Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in primates
Journal: Vaccine

Title: CIGB-247 vaccine breaks immunological tolerance to VEGF in animals
Journal: Biotecnología Aplicada

Title: Olive baboons as a non-human primate model for dengue-2 virus replication
Journal: Infectious Diseases

Title: Proof of concept of heterologous prime–boost dengue vaccine strategy in primates
Journal: Biotecnología Aplicada

Conclusion

Dr. Jorge Castro is a highly suitable candidate for the Best Researcher Award. His outstanding achievements in dengue immunology, vaccine development, and biomedical sciences demonstrate his dedication to advancing public health and scientific knowledge. With continued focus on expanding his recent publication output and international collaborations, Dr. Jorge Castro candidacy for this award is very strong and commendable.

Eishah Mohsen | Biotechnology | Best Researcher Award

Published on by Molecular Biologist

Mrs. Eishah Mohsen | Biotechnology | Best Researcher Award 

Lecturer | University of Aden | Yemen

Mrs. Eishah Mohsen is a Yemeni scholar in the field of Chemistry, recognized for her outstanding academic achievements and research contributions. She has pursued higher education with consistent distinction and currently continues her doctoral studies at the University of Aden. Her research centers on phytochemical analysis, medicinal plant studies, and the synthesis of bioactive compounds with potential applications in medicine and pharmacology. Alongside her academic research, she has maintained a strong presence in teaching and mentoring, guiding undergraduate and postgraduate students in chemistry. Her work highlights the intersection of traditional medicine and modern analytical chemistry, bridging scientific innovation with cultural knowledge. Through her dedication, Mrs. Mohsen has published in respected journals, contributed significantly to the understanding of bioactive plant compounds, and advanced eco-friendly approaches in nanotechnology. Her career reflects a commitment to science, education, and community service, making her an exemplary candidate for recognition.

Professional Profile

Scopus

Education

Mrs. Eishah Mohsen began her academic career at the University of Aden, where she graduated with a Bachelor’s degree in Chemistry from the College of Education with the highest honors. She continued her academic journey at the same institution, completing a Master’s degree in Chemistry with a thesis focused on the proximate and phytochemical analysis of medicinal plants from Yafea, Yemen. Her postgraduate performance was distinguished by excellent results, earning her recognition as the top graduate in her program. Currently, she is pursuing a doctoral degree in Chemistry at the University of Aden. Her Ph.D. research focuses on advanced phytochemical studies, bioactivity screening, and the synthesis of novel compounds derived from traditional medicinal plants. This academic journey demonstrates her consistent excellence, her determination to contribute to chemistry and applied sciences, and her ability to build on Yemen’s natural resources to achieve impactful scientific outcomes.

Experience

Mrs. Eishah Mohsen has accumulated extensive teaching and academic experience. She began her career as a lecturer of physical chemistry at the College of Zanzibar, Abyan University, where she taught and guided students for several years. Following this role, she joined the University of Aden as a lecturer in the Department of Chemistry at the Faculty of Science and Education, specializing in inorganic chemistry. In addition to her teaching duties, she has been an active faculty member in the Department of Chemistry at the Faculty of Education, University of Aden. Her teaching career has been supported by training courses in computer applications, scientific software, and English proficiency, which have strengthened her academic capabilities. Through her experience, she has contributed to curriculum development, student mentoring, and academic activities, building a strong reputation as an educator dedicated to advancing chemistry education and research within Yemen and beyond.

Research Interest

Mrs. Eishah Mohsen research interests focus on phytochemistry, natural product chemistry, and the identification of bioactive compounds in medicinal plants. She has conducted significant work in the phytochemical analysis of Yemeni flora, applying advanced techniques such as chromatography-mass spectrometry and HPLC-ESI-MS to characterize bioactive substances. Her research explores the biological activities of plant-derived compounds, including antimicrobial, antioxidant, and anticancer properties. Beyond phytochemistry, she has developed an interest in bioinorganic chemistry, particularly in the synthesis and characterization of metal ion–bioflavonoid complexes and their biological applications. Another key area of her work is eco-friendly nanotechnology, especially the green synthesis of nanoparticles from medicinal plants, which show promising biomedical potential. By combining traditional medicinal knowledge with modern scientific methods, her research contributes to global efforts in sustainable healthcare solutions while highlighting the untapped potential of Yemen’s plant biodiversity.

Awards & Honors

Mrs. Eishah Mohsen has consistently demonstrated academic excellence throughout her career. She received multiple awards for outstanding performance during her undergraduate studies at the College of Zanzibar, which highlighted her dedication and ability to excel among her peers. At the University of Aden, she earned the Certificate of Academic Excellence for ranking first in her Bachelor’s program, and later, she achieved the same recognition in her Master’s program. She was also awarded a Certificate of Merit from the Center for Science and Technology at the University of Aden for her scientific contributions. These recognitions reflect her consistent pursuit of excellence in both education and research. The honors she has received are a testament to her commitment to advancing chemistry, her leadership in academic achievement, and her ability to inspire students and colleagues through her dedication and scholarly accomplishments.

Top Noted Publications

Mrs. Eishah Mohsen has authored several significant research papers published in reputable scientific journals. Her works include:

1. Title: Phytochemical analysis and antimicrobial screening of selected Yemeni folk medicinal plants

  • Journal: Journal of Medicinal Plants Studies

  • Year: 2019

2. Title: Chromatography-mass spectrometry analysis of some bioactive compounds in two Yemeni medicinal plants

  • Journal: Arabian Journal of Scientific Research

  • Year: 2021

3. Title: HPLC-ESI-MS analysis of some bioactive substances in two Yemeni medicinal plants

  • Journal: Electronic Journal of University of Aden for Basic and Applied Sciences (EJUA-BA)

  • Year: 2020

4. Title: Proximate analysis of four medicinal plants belonging to the Lamiaceae and Moraceae family of Yafea/Yemen

  • Journal: University of Aden Journal of Natural and Applied Sciences

5. Title: Phytochemical analysis of four medicinal plants belonging to the Lamiaceae and Moraceae family of Yafea/Yemen

  • Journal: University of Aden Journal of Natural and Applied Sciences

6. Title: Synthesis, characterization, and bioactivity evaluation of several divalent transition metal ion–bioflavonoid complexes

  • Journal: Results in Chemistry

  • Year: 2024

Conclusion

Mrs. Eishah Mohsen is a highly dedicated researcher whose academic achievements, teaching excellence, and impactful research on medicinal plants and green chemistry make her a strong contender for the Best Researcher Award. Her work contributes to advancing scientific knowledge with practical health and environmental applications. With continued efforts to expand her international collaborations and visibility, she holds significant potential to emerge as a leading researcher in her field.

Heng Zhang | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Heng Zhang | Molecular Biology | Best Researcher Award 

Lecturer | Nankai University | China

Dr. Zhang Heng is a Lecturer in Pharmacology at Nankai University, specializing in investigating the molecular mechanisms underlying malignant tumor progression and developing innovative drug therapies. He earned his B.S., M.S., and Ph.D. in Pharmaceutical Sciences from Nankai University, completing his doctoral studies with high distinction. Since joining the faculty as a lecturer, he has been actively engaged in teaching, mentoring, and advancing cutting-edge cancer research. Dr. Zhang has published multiple high-impact papers in prestigious SCI-indexed journals, including Molecular Cell, Signal Transduction and Targeted Therapy, and Advanced Materials. His scholarly contributions include original research on extrachromosomal DNA, tumor stem cell propagation, and nanomedicine-based immunotherapy. He also holds four patent applications and has received several top academic and innovation awards. Through his research and academic leadership, Dr. Zhang continues to make significant contributions toward improving the understanding of cancer biology and developing novel therapeutic strategies for clinical application.

Professional Profile

ORCID

Education

Dr. Zhang Heng pursued his higher education entirely at Nankai University, a leading institution in China recognized for excellence in pharmaceutical research. He began his academic journey with a Bachelor of Science degree in Pharmaceutical Sciences, where he built a strong foundation in pharmacology, molecular biology, and medicinal chemistry. Continuing at Nankai, he completed his Master of Science degree, focusing on the molecular biology of tumors and early drug discovery methodologies. His master’s research involved extensive laboratory experiments, including molecular cloning, protein analysis, and tumor cell line studies. Dr. Zhang then earned his Ph.D. in Pharmaceutical Sciences, conducting advanced research on the molecular mechanisms driving cancer progression and identifying new targets for therapeutic intervention. His doctoral studies resulted in multiple publications in internationally recognized journals. This academic path, marked by consistent excellence and research productivity, has equipped him with the knowledge and skills essential for his role as an independent researcher and educator.

Experience

Following the completion of his doctoral studies, Dr. Zhang Heng was appointed Lecturer at the College of Pharmacy, Nankai University. In this role, he has been responsible for delivering lectures in pharmacology, supervising undergraduate and graduate students, and leading research initiatives in molecular oncology. He has designed and managed multiple research projects, often collaborating with interdisciplinary teams, and has successfully bridged fundamental science with translational medicine. His experience encompasses conducting high-level molecular biology research, managing laboratory operations, and contributing to scientific publications as both first and corresponding author. He has filed patents for innovative drug delivery systems and tumor immunotherapies, demonstrating the applied impact of his work. Beyond laboratory research, Dr. Zhang has participated in national-level innovation competitions and academic conferences, presenting his findings to peers and experts in the field. His experience reflects a balance of teaching excellence, research innovation, and contribution to the broader scientific community.

Research Interest

Dr. Zhang Heng’s research interests lie at the intersection of cancer biology, molecular pharmacology, and drug innovation. He investigates the fundamental mechanisms that drive the malignant progression of tumors, including the role of extrachromosomal DNA, R-loop dynamics, and vasculogenic mimicry. His work also explores how specific proteins and epigenetic factors regulate tumor growth, immune evasion, and stem cell maintenance. In addition to basic research, Dr. Zhang focuses on developing new therapeutic strategies, such as tumor-targeted nanomedicines, biomimetic exosomes, and in situ tumor vaccines. He aims to integrate these novel approaches into translational medicine frameworks, ultimately leading to more effective, personalized cancer treatments. His interdisciplinary methodology combines molecular biology, pharmacology, nanotechnology, and immunotherapy, with the overarching goal of creating clinically applicable solutions for some of the most aggressive and treatment-resistant cancers. This research focus reflects both scientific curiosity and a commitment to advancing healthcare outcomes.

Award

Dr. Zhang Heng has been recognized for his outstanding research achievements, innovative contributions, and academic excellence through multiple prestigious awards. He received the Second Prize of the Tianjin Science and Technology Progress Award, which acknowledges impactful scientific advancements with practical applications. His innovative work in drug development and cancer therapy earned him the Gold Award at the China International “Internet Plus” Innovation and Entrepreneurship Competition. In recognition of his leadership, scientific merit, and contributions to society, he was awarded the Tianjin May Fourth Youth Medal. While a student, Dr. Zhang received the Zhou Enlai Scholarship, the highest honor granted by Nankai University, and was named Nankai University Student of the Year. These distinctions highlight not only his research excellence but also his dedication to innovation, community engagement, and the advancement of pharmacological sciences on both a national and international level.

Top Noted Publication

Dr. Zhang Heng has authored a series of impactful publications in high-ranking scientific journals, contributing significantly to the fields of molecular oncology and drug development. His research outputs span mechanistic cancer biology studies, novel therapeutic approaches, and the application of nanotechnology in tumor immunotherapy. These publications have been cited in multiple peer-reviewed articles, demonstrating their influence within the global scientific community. His work continues to inform and inspire ongoing research in cancer treatment innovation.

Publications list (single-line prompt):

Title: Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1–Lig3–PARylation complex
Journal: Molecular Cell
Year: 2025

Title: MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells
Journal: Signal Transduction and Targeted Therapy
Year: 2021

Title: Biomimetic Immunosuppressive Exosomes that Inhibit Cytokine Storms Contribute to the Alleviation of Sepsis
Journal: Advanced Materials
Year: 2022

Title: Magnetic sculpture-like tumor cell vaccines enable targeted in situ immune activation and potent antitumor effects
Journal: Theranostics
Year: 2025

Title: Vitamin D binding protein (VDBP) hijacks Twist1 to inhibit vasculogenic mimicry in hepatocellular carcinoma
Journal: Theranostics
Year: 2024

Conclusion

Dr. Zhang Heng is a highly suitable candidate for the Research for Best Researcher Award. His combination of scientific excellence, innovation, and societal impact aligns well with the award’s criteria. With continued growth in global collaboration and academic leadership, he has the potential to become a leading figure in pharmacology and cancer research worldwide.

 

Juan Cristobal Garcia Canedo | Biotechnology | Best Researcher Award

Published on by Molecular Biologist

Dr. Juan Cristobal Garcia Canedo | Biotechnology | Best Researcher Award 

Professor | Monterrey Institute of Technology | Mexico

Prof. Juan Cristóbal García Cañedo is a distinguished academic and researcher at Tecnológico de Monterrey, Mexico, with over three decades of combined industry, research, and teaching experience. His career began in the private agricultural and food industry, Transitioning into academia, he has dedicated another decade to impactful research and teaching in engineering, specializing in microalgae cultivation, carotenoids, and sustainability. Prof. García Cañedo has published extensively, including four indexed journal articles, three book chapters, and an edited book on photosynthesis. His research focuses on innovative microalgae applications for biomass, metabolite production, and carbon capture. He has actively collaborated with non-governmental organizations and industry, serving as a consultant in environmental sustainability projects. His work bridges theoretical science and practical applications, earning him recognition as a leader in sustainable biotechnology and applied environmental engineering.

Professional Profile

Scopus

ORCID

Education

Prof. García Cañedo’s educational background reflects a solid foundation in engineering and applied sciences, supported by professional certifications in food safety and quality management. He holds specialized training in Hazard Analysis and Critical Control Points (HACCP) and is a certified Preventive Controls Qualified Individual (PCQI), demonstrating his expertise in food safety standards. His studies have allowed him to integrate engineering principles with biological sciences, particularly in microalgae biotechnology. Over the course of his career, he has pursued continuous professional development to stay at the forefront of emerging technologies. His education has been complemented by international academic collaborations, enhancing his perspective and methodology. This combination of formal education, professional certifications, and global engagement has positioned him to address sustainability challenges through innovative engineering solutions, enabling impactful contributions to both academia and industry in areas such as renewable biomass production, environmental protection, and sustainable food systems.

Experience

Prof. García Cañedo’s career encompasses a unique blend of industry, academia, and research expertise. In the agricultural and food industries, he spent more than a decade in roles involving quality control, production optimization, product development, and commercialization, gaining valuable practical insights. In academia, he has served over ten years as an engineering professor, teaching and mentoring students in biotechnology and environmental engineering. His research career spans another decade, with a focus on microalgae cultivation, carotenoid production, and environmental applications for carbon capture. He has presented at multiple international congresses and has acted as an advisor to non-governmental organizations in Mexico, contributing to reforestation and sustainability initiatives. His scholarly output includes indexed journal articles, book chapters, and an edited book. His patent on PET plastic recycling showcases his capacity for translating research findings into viable industrial innovations, underlining his dual focus on academic excellence and practical problem-solving.

Research Interest

Prof. García Cañedo’s research interests lie at the convergence of biotechnology, environmental sustainability, and applied engineering. His primary focus is the cultivation of microalgae for biomass and metabolite production, with emphasis on carotenoids and lutein for visual health applications. He is particularly interested in fed-batch cultivation techniques, which enable precise nutrient control to optimize yield and quality. Another key aspect of his research is the utilization of microalgae for carbon capture, contributing to climate change mitigation strategies. He is also engaged in the integration of automatic control systems into microalgae cultivation, enhancing scalability and efficiency. His investigations extend to sustainable resource management, plastic waste recycling, and renewable energy production from biomass. By combining process engineering, control theory, and biological systems, his work seeks to develop next-generation technologies that meet the dual objectives of economic feasibility and environmental stewardship, thereby addressing critical global challenges.

Awards

Prof. García Cañedo has earned recognition for his research excellence and contributions to sustainable biotechnology. His nomination for the Best Researcher Award underscores his impact in advancing microalgae biotechnology and environmental engineering. His scholarly publications, particularly in the development of sustainable cultivation systems and bioactive compound production, have garnered citations and interest from academic peers worldwide. Participation as a presenter in several international congresses has demonstrated his commitment to global scientific exchange. His research achievements are complemented by industry-relevant innovations, including a patent for PET plastic recycling, which illustrates the practical applicability of his work. Collaborations with non-governmental organizations on reforestation and carbon capture projects further highlight his dedication to environmental improvement. Collectively, these accomplishments reflect his ability to produce both academic and societal benefits, positioning him as a strong candidate for recognition in the fields of research, sustainability, and applied engineering innovation.

Top Noted Publications

Prof. García Cañedo has authored impactful works, including indexed journal articles, book chapters, and an edited book. Selected publications

Title: Nutrition Therapy in the Prevention of Type 2 Diabetes
Journal: American Dietetic Association
Year: 2011

Title: Biological and technical aspects of carotenoid production by microalgae
Journal: Algal Research
Year: 2016

Title: Production of carotenoids by microalgae: achievements and challenges Journal: IntechOpen
Year: 2016

Title: Automatic control applied to microalgae cultures
Journal: Elsevier
Year: 2023

Conclusion

Prof. Juan Cristóbal García Cañedo presents a compelling case for the Best Researcher Award. His blend of industrial expertise, academic achievements, and applied research innovations in sustainability reflects both depth and breadth in scholarly contribution. With strategic emphasis on increasing high-impact publications and global networking, his research trajectory shows significant promise for continued influence in the scientific community.

 

Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award

Published on by Molecular Biologist

Dr. Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award 

Scientific Research Lead | Memorial Sloan Kettering Cancer Center | United States

Dr. Ingrid Tatiana Erazo is a distinguished cancer researcher and Scientific Research Lead at Memorial Sloan Kettering Cancer Center (MSKCC) with extensive experience in translational oncology. She earned her PhD Summa Cum Laude in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, where she pioneered research on the ERK5 signaling pathway. Her early postdoctoral work led to the discovery of the mechanism of action for ABTL-0812, an autophagy-inducing anticancer agent now in Phase III clinical trials. Over the past decade at MSKCC, she has advanced understanding of PRMT5 inhibition, therapeutic resistance, and biomarker development for precision oncology. She currently leads initiatives integrating liquid biopsy diagnostics for early cancer detection and is spearheading global health equity programs, including the creation of Brazil’s first national referral network for cancer clinical trials. Her work bridges molecular discoveries with clinical application, driving advancements in both targeted therapies and diagnostic tools.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Dr. Erazo earned her PhD in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, graduating Summa Cum Laude. Her doctoral research focused on dissecting the ERK5 signaling pathway and its role in cancer cell proliferation and survival. She used Tandem Affinity Purification to map ERK5’s interactome, uncovering novel noncanonical mechanisms and post-translational modifications such as SUMOylation that opened new therapeutic opportunities. Collaborating with Dana-Farber Cancer Institute at Harvard, she co-developed potent and selective ERK5 inhibitors, providing valuable pharmacological tools for cancer research. Her academic training combined molecular biology with translational oncology, giving her a unique foundation to move seamlessly from bench research to clinical applications. She also pursued advanced training in biomarker discovery and molecular diagnostics, enabling her to contribute to projects that merge fundamental discoveries with practical solutions for cancer detection, prognosis, and treatment optimization in a variety of clinical contexts.

Experience

Dr. Erazo’s professional career spans more than 20 completed research projects and leadership in multiple ongoing studies, covering molecular oncology, biomarker discovery, and therapeutic resistance. At MSKCC, she elucidated the mechanism of action of PRMT5 inhibitors and identified MUSASHI-2 as a driver of drug resistance in hematologic malignancies, leading to innovative combination therapy strategies. She developed liquid biopsy-based diagnostics for aggressive prostate cancers and integrated proteomic biomarkers into clinical research pipelines. In her earlier postdoctoral role at Ability Pharmaceuticals, she was instrumental in advancing ABTL-0812 to clinical trials by defining its mechanism and identifying relevant biomarkers. She has partnered with global pharmaceutical and biotech companies, including GlaxoSmithKline, Biodesix Inc., and Guardant Health. Her work also extends to global health initiatives, such as establishing Brazil’s first national referral network for cancer clinical trials with molecular profiling, aiming to address disparities in cancer care and ensure equitable access to precision oncology.

Research Interest

Dr. Erazo’s research focuses on cancer biology, mechanisms of drug resistance, biomarker discovery, and precision oncology. She has a particular interest in hematological malignancies and aggressive solid tumors where therapeutic resistance significantly impacts patient outcomes. Her work applies genome-wide CRISPR synthetic lethal screening, proteomics, and high-throughput drug screening to identify cancer vulnerabilities and inform new treatment strategies. She is advancing diagnostic methods through liquid biopsy technology, enabling early and non-invasive tumor detection and monitoring, with a focus on neuroendocrine prostate cancer. Dr. Erazo also addresses global health inequities by developing clinical trial networks in underrepresented regions and incorporating genetic ancestry into study designs to improve population-specific therapeutic approaches. By combining basic molecular research with translational and clinical applications, she aims to ensure that future cancer therapies and diagnostics are effective across diverse populations and accessible beyond high-resource healthcare settings.

Awards

Dr. Erazo’s scientific achievements have positioned her as a leader in translational cancer research and a nominee for the Molecular Biology Contribution Award. She is recognized for her groundbreaking work on ERK5 signaling, the clinical biomarker development for ABTL-0812, and the identification of MUSASHI-2 as a therapeutic resistance driver. Her contributions to liquid biopsy-based proteomic biomarkers for detecting lineage transformation in prostate cancer have advanced early diagnostic capabilities in precision oncology. She has also been a driving force behind the establishment of Brazil’s first national clinical trial referral network, demonstrating a strong commitment to global health equity. Her work, cited extensively in scientific literature, reflects both scientific rigor and real-world clinical impact. These accomplishments highlight her role as both a laboratory innovator and a global health strategist, whose research has shaped cancer treatment strategies and advanced diagnostic development on an international scale.

Top Noted Publications

Dr. Erazo has authored over 20 peer-reviewed articles in high-impact journals, including Annals of Oncology, Nature Communications, Autophagy, and Clinical Cancer Research. Her research spans mechanistic cancer biology, drug development, and biomarker-driven clinical applications. She has contributed to significant discoveries such as mapping the ERK5 interactome, elucidating the mechanism of action for ABTL-0812, and identifying resistance biomarkers for hematological malignancies. Her publications often emerge from collaborative projects that integrate molecular biology, pharmacology, and clinical trial data, reflecting her multidisciplinary approach to advancing oncology research. The high citation count of her work underscores its influence and the adoption of her findings by researchers and clinicians worldwide. Her studies have informed clinical trial design, therapeutic development, and diagnostic tool implementation, bridging the gap between basic science and patient-centered outcomes in cancer care.

Selected Publications (Single-Line Format)

Title: Erazo T, et al. The new antitumor drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels
Journal: Nature Communications
Cited by 312

Title: Erazo T, et al. Inhibition of PRMT5 in lymphomas overcomes therapeutic resistance via MUSASHI-2 modulation
Journal: Clinical Cancer Research
Cited by 145

Title: Erazo T, et al. ERK5 kinase activity-independent functions in cancer: implications for drug development
Journal: Autophagy
Cited by 110

Title: Erazo T, et al. Blood-based proteomic biomarkers for early detection of lineage plasticity in prostate cancer
Journal: Annals of Oncology
Cited by 35

Title: Erazo T, et al. High-throughput screening of FDA-approved drugs for novel therapeutic combinations in lymphoma
Journal: Molecular Oncology
Cited by 28

Conclusion

Dr. Ingrid Tatiana Erazo’s pioneering research, translational breakthroughs, and commitment to equitable precision oncology position her as an outstanding candidate for the Research for Molecular Biology Contribution Award. Her work exemplifies how rigorous molecular biology can directly shape novel therapeutics, diagnostics, and healthcare systems globally. Awarding her would recognize not only her individual achievements but also her vision for transforming cancer care through innovation and inclusivity.

 

Moutih Rafei | Immunology | Best Researcher Award

Published on by Molecular Biologist

Dr. Moutih Rafei | Immunology | Best Researcher Award 

Full Professor | University of Montreal | Canada

Dr. Moutih Rafei is a Full Professor at the Université de Montréal’s Faculty of Medicine, Department of Pharmacology and Physiology. With extensive expertise in cellular and molecular immunology, he has significantly advanced the fields of immuno-oncology, vaccine engineering, and immune modulation. He earned his Ph.D. in Experimental Medicine from McGill University, followed by a post-doctoral fellowship in Molecular Biology at Université de Montréal, where he later established his own research laboratory. His group focuses on developing novel immune-based therapeutic strategies, several of which are progressing toward clinical application. Dr. Rafei has authored numerous high-impact publications, book chapters, and patents, contributing both to academic knowledge and industrial innovation. His leadership extends to mentoring young scientists and serving as an editor for scientific journals. His work continues to influence immunological research and therapeutic development, addressing complex diseases such as cancer, autoimmune disorders, and infectious conditions.

Professional Profile

Scopus

Google Scholar

Education

Dr. Rafei completed his B.Sc. Honours in Immunology at McGill University, conducting an honours thesis on Giardia lamblia transmission-blocking DNA vaccines. He pursued his Ph.D. in Experimental Medicine at McGill University, working under the supervision of Dr. Jacques Galipeau on fusokine design as a novel therapeutic strategy for immunosuppression. Following this, he undertook a post-doctoral fellowship at Université de Montréal under Dr. Claude Perreault, where he specialized in innate and classical CD8 T-cell development and maturation. Complementing his scientific training, he also completed a Mini-Entrepreneurship Program at the HEC-Poly-UdeM Entrepreneurship Centre, gaining strategic and managerial skills applicable to biotech ventures. This combination of academic depth and entrepreneurial insight has enabled Dr. Rafei to successfully navigate the interface between fundamental research and its translation into clinical and industrial solutions, shaping his career as both an academic leader and biotech innovator.

Experience

Dr. Rafei holds extensive academic and industrial experience, combining innovative research with strategic leadership in biotechnology. As a Full Professor at Université de Montréal, he leads a dynamic research program focused on immune engineering and translational immunotherapy. His industrial roles include serving as Chief Scientific Officer at Defence Therapeutics, where he oversaw pre-clinical development of oncology and vaccine programs, and Head of Discovery at Medicenna Therapeutics, managing the IL-2 Superkine program currently in clinical trials. He is also the Founder and CEO of Axiom Services Inc., providing consulting and R&D guidance to pharmaceutical and biotechnology companies. His responsibilities have included directing large-scale pre-clinical studies, preparing regulatory submissions for clinical trials, and presenting research at major international conferences. Through his dual academic and industry roles, Dr. Rafei has successfully bridged fundamental science and applied product development, positioning himself as a key contributor to innovation in immuno-oncology.

Research Interest

Dr. Rafei’s research centers on developing advanced immunotherapies for severe diseases, particularly cancer. His work covers T-cell biology, fusokine engineering, and mesenchymal stromal cell-based vaccines. He has pioneered the design of engineered mesenchymal stromal cells capable of presenting antigens for cancer immunotherapy, developed non-IL1Ralpha-binding IL-2 variants for oncology, and advanced γδ T-cell-based therapeutic platforms. He also leads projects utilizing the proprietary Accum® technology to enhance the targeted delivery of antibody-drug conjugates, cancer vaccines, and infectious disease vaccines. Additionally, his group explores genetic and pharmacological strategies to convert mesenchymal stromal cells into antigen-presenting cells, expanding potential treatments for oncology, autoimmune diseases, and transplantation. Integrating molecular biology, immune engineering, and translational medicine, his research aims to transform fundamental discoveries into effective, scalable, and clinically relevant therapies that address unmet medical needs in immunology.

Awards

Dr. Rafei has received more than twenty awards and recognitions that highlight his exceptional contributions to the fields of immunology and translational medicine. These honors acknowledge his pioneering work in cytokine and fusokine engineering, vaccine development, and mesenchymal stromal cell-based immunotherapies. His ability to integrate molecular innovations into practical clinical applications has earned him recognition in both academic and industrial sectors. Awards have also acknowledged his role as a mentor, fostering the growth of emerging scientists, and his leadership in driving collaborative research across disciplines and borders. His keynote presentations at prestigious international conferences further demonstrate his influence and leadership in the scientific community. The breadth of these awards reflects his sustained commitment to excellence, innovation, and the advancement of immune-based strategies for the treatment of complex and life-threatening diseases.

Top Noted Publications

Dr. Rafei has authored over sixty high-impact peer-reviewed articles, five reviews, two book chapters, one monograph, and holds six patents. His research has been published in leading journals such as Molecular Cancer, Frontiers in Immunology, and Cancer Immunology Research. With a citation index exceeding two thousand, his work has influenced both academic research and industry practices in immuno-oncology. His publications cover diverse topics, including engineered mesenchymal stromal cells for cancer vaccination, cytokine-fusion proteins, and novel delivery systems using the Accum® technology. In addition to original research, he has contributed reviews synthesizing developments in immune-based therapies.

Title: Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner – M Rafei, PM Campeau, A Aguilar-Mahecha, M Buchanan, P Williams, et al.

Journal: The Journal of Immunology

Year: 2009

Cited by 462.

Title: Mesenchymal stromal cell–derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction – M Rafei, J Hsieh, S Fortier, MY Li, S Yuan, et al.

Journal: Blood

Year: 2008

Cited by 309.

Title: Cell therapy: types, regulation, and clinical benefits – AEH El-Kadiry, M Rafei, R Shammaa.

Journal: Frontiers in Medicine

Year: 2021

Cited by 238.

Title: Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis – M Rafei, E Birman, K Forner, J Galipeau.

Journal: Molecular Therapy

Year: 2009

Cited by 204.

Title: Nociceptor neurons affect cancer immunosurveillance – M Balood, M Ahmadi, T Eichwald, A Ahmadi, A Majdoubi, et al.

Journal: Nature

Year: 2022

Cited by 200.

Title: A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties – M Rafei, J Hsieh, S Zehntner, MY Li, K Forner, et al.

Journal: Nature Medicine

Year: 2009

Cited by 170.

Title: Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR 2 – K Mojumdar, F Liang, C Giordano, C Lemaire, G Danialou, et al.

Journal: EMBO Molecular Medicine

Year: 2014

Cited by 155.

Title: Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome – PM Campeau, M Rafei, MN Boivin, Y Sun, GA Grabowski, et al.

Journal: Blood

Year: 2009

Cited by 112

Conclusion

Dr. Moutih Rafei’s exceptional contributions to immunotherapy, translational science, and biotechnology innovation position him as an outstanding candidate for the Best Researcher Award. His career demonstrates a rare combination of groundbreaking scientific insight, creative problem-solving, and the capacity to turn laboratory discoveries into impactful therapies. Recognizing his achievements through this award would honor his significant contributions and encourage further advancements that have the potential to transform patient care globally.

Androniki Kretsovali | Molecular Neuroscience | Women Researcher Award

Published on by Molecular Biologist

Dr. Androniki Kretsovali | Molecular Neuroscience | Women Researcher Award 

Research Director | Institute of Molecular Biology & Biotechnology | Greece

Dr. Androniki Kretsovali is a distinguished Greek molecular biologist currently serving as Research Director at the Institute of Molecular Biology & Biotechnology (IMBB) within the Foundation for Research and Technology-Hellas (FORTH). She earned her B.Sc. in Chemistry from Aristotle University of Thessaloniki, followed by a DEA in Biochemistry from the University of Paris XI, and a Ph.D. in Biochemistry from the University of Paris VII. She also completed postdoctoral fellowships at Paris VII and at IMBB in Heraklion. Throughout her career, she has advanced through multiple positions at IMBB, from research contracts and staff scientist roles to principal researcher and now Research Director. Dr. Kretsovali has played a pivotal role in both research and education, supervising numerous Ph.D., M.Sc., and undergraduate students. Her scientific focus on stem cell pluripotency, epigenetic regulation, and neural stem cell biology has positioned her as a leading figure in molecular biology research in Greece.

Professional Profile

Scopus

Google Scholar

Education

Dr. Kretsovali’s academic foundation began with a Bachelor’s degree in Chemistry from Aristotle University of Thessaloniki. She then pursued advanced studies in France, earning a Diplôme d’Études Approfondies (DEA) in Biochemistry from the University of Paris XI, followed by a Doctorate (Ph.D.) in Biochemistry from the University of Paris VII. Furthering her expertise, she completed postdoctoral fellowships at the University of Paris VII and at the Institute of Molecular Biology & Biotechnology in Heraklion, Greece. This combination of foundational scientific education in Greece and specialized research training in France equipped her with the necessary skills to investigate complex molecular and cellular mechanisms. Her international academic background provided her with a strong theoretical base, extensive laboratory experience, and a multidisciplinary perspective on molecular biology, epigenetics, and stem cell research, laying the groundwork for her future achievements as a senior research leader.

Experience

Dr. Kretsovali has had a progressive research career at the Institute of Molecular Biology & Biotechnology (IMBB) within FORTH. She began with a research contract before being appointed as Staff Scientist B, followed by promotion to Staff Scientist A. She then served as Principal Researcher before her appointment as Research Director. Earlier in her career, she worked as an Adjunct Assistant Professor of Biochemistry at the University of Crete, where she taught undergraduate courses in Biochemistry. Beyond her primary research roles, she has been actively involved in postgraduate education, delivering lectures for various master’s and doctoral programs at the University of Crete and the University of Athens. She has supervised numerous graduate and undergraduate students in laboratory research projects, contributing to both their scientific development and to the advancement of her research programs. Her experience spans molecular biology, stem cell science, epigenetics, and neurodegeneration research.

Research Interest

Dr. Kretsovali’s research focuses on the molecular mechanisms that regulate embryonic stem cell pluripotency, induced pluripotent stem cell reprogramming, and neural stem cell differentiation and survival. Her work examines how transcriptional and epigenetic regulators, as well as signaling pathways, control stem cell fate decisions. Using a combination of gene silencing, genome-wide approaches, proteomics, small molecule interventions, and biomaterials, her team investigates the balance between self-renewal and differentiation. In recent years, she has explored the neuroprotective role of the Promyelocytic Leukemia Protein (PML) in models of neurodegeneration and neuroinflammation, particularly in the context of Alzheimer’s disease. Her group also studies synthetic microneurotrophins and their potential in neural repair strategies. This dual focus on stem cell biology and neurodegeneration not only advances fundamental understanding of cell fate regulation but also has potential applications in regenerative medicine and the treatment of neurodegenerative disorders.

Awards

No specific awards, honors, or recognitions are documented in the provided material or in publicly accessible databases. It is possible that Dr. Kretsovali has received acknowledgments for research excellence, academic contributions, or institutional service that are not currently listed in the available sources. Her long-standing leadership roles, significant research output, and extensive contributions to postgraduate education and mentorship suggest that she is highly regarded within her professional community. For a complete awards record, further institutional or personal documentation would be required to supplement this application.

Top Noted Publications

Selected publications with hyperlinks, journal names, and titles:

Title: Promyelocytic Leukemia Protein Regulates Stem Cell Pluripotency Through Novel Sumoylation Targets

journal: International Journal of Molecular Sciences

Year: 2023

Cited: 42 articles

Title: Promyelocytic Leukemia Protein Regulates Angiogenesis and Epithelial-Mesenchymal Transition to Limit Metastasis in MDA-MB-231 Breast Cancer Cells

journal: Molecular Oncology

Year: 2022

Cited: 56 articles

Title: Promyelocytic Leukemia Protein and Stem Cells: From Cancer to Pluripotency

journal: International Journal of Developmental Biology

Year: 2021

Cited: 38 articles

Title: Adenovirus Fibers as Ultra-Stable Vehicles for Intracellular Nanoparticle and Protein Delivery

journal: Biomolecules

Year: 2021

Cited: 27 articles

Title: Promyelocytic Leukemia Protein Controls Breast Cancer Cell Proliferation by Modulating Forkhead Transcription Factors

journal: Molecular Oncology

Year: 2020

Cited: 44 articles

Title: Designer Amyloid Cell-Penetrating Peptides for Potential Use as Gene Transfer Vehicles

journal: Biomolecules

Year: 2020

Cited: 19 articles

Title: Groucho Related Gene 5 (GRG5) is Involved in Embryonic and Neural Stem Cell State Decisions

journal: Scientific Reports

Year: 2019

Cited: 51 articles

Conclusion

Dr. Androniki Kretsovali is an exceptional candidate for the Research for Women Researcher Award. Her career blends scientific excellence, innovation, leadership, and mentorship. Her groundbreaking contributions to stem cell biology and neurodegeneration research not only advance fundamental science but also hold promise for addressing urgent societal health challenges. Recognizing her with this award would honor a researcher whose work embodies the spirit of excellence, persistence, and inspiration for the next generation of women scientists.

 

Roberto G Carbone | Therapeutic Management | Best Researcher Award

Published on by Molecular Biologist

Prof. Dr. Roberto G Carbone | Therapeutic Management | Best Researcher Award 

Professor of Medicine | University of Genoa | Italy

Prof. Roberto G Carbone is a distinguished Professor of Medicine and Senior Consultant for Interstitial Lung Disease and Pulmonary Hypertension at the University of Genoa, Italy. With decades of experience, his expertise has significantly advanced respiratory medicine through clinical practice, international education, and research. He is a Fellow of the Royal Society of Medicine and of the American College of Chest Physicians. He has been a leading member of international organizations such as the American Thoracic Society and the European Respiratory Society. Prof. Carbone has authored scientific publications and several books on pulmonary vascular disorders and lung transplantation. He is actively involved in editing leading medical journals, including The Lancet and Frontiers in Pulmonary Medicine. His clinical and academic leadership has had a profound global impact on improving outcomes for patients with complex pulmonary diseases. His ongoing research in idiopathic pulmonary fibrosis positions him as a global pioneer in respiratory medicine.

Professional Profile

Scopus

ORCID

Education

Prof. Roberto G Carbone completed his medical degree at the University of Genoa, where he also obtained two specializations in Respiratory Diseases and Respiratory Pathophysiology. He pursued advanced international education, including a Master’s degree in Respiratory Medicine from the Royal Brompton Hospital in London, United Kingdom. Additionally, he completed several specialized master programs: Pulmonary Hypertension at the University of Michigan, Ann Arbor (USA); Bronchial Asthma at National Jewish Health, Denver (USA); and COPD and Interstitial Lung Diseases at the University of Montpellier, France. He is registered with the General Medical Council in the United Kingdom and maintains long-standing memberships in prominent medical societies including the American Thoracic Society and European Respiratory Society. His diverse educational background across multiple countries and centers of excellence has equipped him with a comprehensive and multidisciplinary perspective in respiratory medicine.

Experience

Prof. Carbone high-level academic and clinical experience in respiratory medicine. He has been a key faculty member at the University of Genoa School of Medicine, serving as Senior Consultant for Interstitial Lung Disease and Pulmonary Hypertension. Internationally recognized, he has held numerous leadership positions, including within the American Thoracic Society’s COPD Steering Committee and the National Quality Forum in the United States. He has been a long-time member of the Editorial Board of CHEST Journal and has contributed to steering committees for lung transplant and cardiovascular disease. He has also been a frequent faculty member or chair at major global medical conferences, shaping discourse on respiratory diseases. His professional affiliations extend to the American College of Chest Physicians, Royal Society of Medicine, and American Heart Association, reflecting a broad and influential career in respiratory health.

Research Interests

Prof. Carbone’s research is centered on Interstitial Lung Disease (ILD), Pulmonary Hypertension (PH), Lung Cancer, Connective Tissue Diseases, Sarcoidosis, Systemic Sclerodermia, and Lung Transplantation. He has been instrumental in developing diagnostic frameworks and treatment approaches for idiopathic pulmonary fibrosis and pulmonary vascular disorders. His work integrates clinical data, molecular biology, and genomics to identify early biomarkers and improve therapeutic outcomes. Currently, he leads the Global Genome Project for Idiopathic Pulmonary Fibrosis in collaboration with the University of Denver, USA. He also contributes to guideline development and multicenter clinical trials in the areas of COPD and ILD. His work on porto-pulmonary hypertension and hepato-pulmonary syndrome has provided a better understanding of these complex syndromes and their treatment options, including the role of lung and liver transplantation. His interdisciplinary research continues to influence global standards in respiratory care and medical education.

Awards

Prof. Carbone has received several notable recognitions throughout his career. He has been consistently selected for leadership roles in top respiratory organizations, including the American Thoracic Society and the National Quality Forum. He has received multiple invitations to chair and deliver keynote lectures at international conferences, reflecting his reputation as a thought leader in pulmonary medicine. His contributions to guideline development and editorial leadership have been recognized with appointments to several prestigious journal boards, including The Lancet and CHEST. These honors reflect his sustained excellence in clinical practice, academic contribution, and research innovation in the field of respiratory medicine.

Top Noted Publications

Prof. Carbone has authored over peer-reviewed articles, with recent high-impact work published in The Lancet and CHEST. His publications focus on idiopathic pulmonary fibrosis, pulmonary hypertension, lung transplantation, and systemic scleroderma. He has also edited five authoritative books, including:

Title: Pulmonary Vascular Disorders
Journal: The Lancet
Citation Count: 123 articles
Year: 2023

Title: Interstitial Lung Disease
Journal: Frontiers in Pulmonary Medicine
Citation Count: 88 articles
Year: 2022

Title: Pulmonary Hypertension in ILD
Journal: CHEST Journal
Citation Count: 95 articles
Year: 2021

Conclusion

Professor Roberto G Carbone is eminently suitable for the Best Researcher Award. His sustained research excellence, global collaborations, and editorial leadership position him as a leader in respiratory and pulmonary medicine. Minor enhancements in reporting academic metrics and mentorship activities could further elevate his candidacy. Nonetheless, his track record reflects the hallmarks of an impactful and visionary medical researcher, fully deserving of this international recognition.

Nader Neiroukh | Cell Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Nader Neiroukh | Cell Biology | Best Researcher Award

High School Principal | An-Najah National University | Palestine

Nader Mohammad Issa Neiroukh is a committed Palestinian educator and school leader whose career spans decades of impactful work in teaching and administration. he has contributed extensively to the development of English language instruction and teacher training in Palestinian and Israeli educational institutions. Currently serving as the principal of Shu’fat Secondary School for Boys, Nader also lectures on teaching methodology at various teacher training colleges. His professional efforts reflect a deep commitment to quality education, inclusive leadership, and peacebuilding through academic engagement. With fluency in Arabic, English, and Hebrew, Nader brings a culturally responsive approach to education. He has participated in international education conferences and training programs, and his career demonstrates a strong blend of practice, pedagogy, and policy insight. His mission is to transform schools into environments that empower students, foster critical thinking, and promote coexistence through dialogue and understanding.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Nader Neiroukh’s educational background combines advanced academic credentials with specialized training in educational leadership and language instruction. He is currently pursuing a doctoral degree in Education, building upon a Master’s degree in Educational Administration. He also holds a diploma in teaching English as a foreign language and a bachelor’s degree in English Literature with a minor in Commerce. His foundational schooling was completed in Ramallah, where he earned his general secondary school certificate. In addition to formal degrees, Nader has completed a wide array of professional development courses in areas such as educational technology, administrative skills, lesson planning, democracy in education, and digital literacy. These qualifications demonstrate his ongoing commitment to educational excellence, instructional innovation, and leadership development. His academic path is both diverse and practical, providing him with a broad understanding of how to lead and reform educational systems in dynamic and multicultural environments.

Experience

Nader Neiroukh has held a wide range of roles across the education sector, encompassing leadership, teaching, and training. He is the current principal of Shu’fat Secondary School for Boys, where he oversees academic planning, staff development, and student affairs. He has served as a teacher trainer for the Ministry of Education and continues to work at colleges of education, training future English language teachers. His earlier roles include teaching English to high school students, university students, and adult learners in various institutions. Notably, he has also contributed to Brigham Young University’s Jerusalem Center, where he supported Arabic language instruction and coordinated educational field trips. His career includes experience in administrative planning, curriculum development, and pedagogical training, spanning public schools, technical colleges, and higher education settings. Nader’s long-standing dedication to education has shaped a professional legacy grounded in inclusivity, innovation, and cross-cultural collaboration.

Research Interest

Nader Neiroukh’s research interests focus on educational leadership, language pedagogy, peace education, and curriculum transformation. He is particularly invested in improving English as a Foreign Language instruction in culturally and linguistically diverse classrooms. His ongoing doctoral research explores effective leadership practices and transformative education in divided or conflict-affected societies. He is also interested in methods for training teachers to become change agents within their communities, with a focus on meaningful learning and digital integration in education. His participation in numerous international conferences reflects his academic engagement in topics such as identity, democracy in education, lesson design, and school-community relationships. Through both practical experience and academic inquiry, Nader seeks to develop educational models that emphasize equity, critical thinking, and collaboration. His research aims to support educators in adapting to evolving pedagogical landscapes while promoting peace and understanding through curriculum design and instructional strategies.

Award

Nader Neiroukh has received recognition and nominations for his outstanding contributions to the field of education, particularly in leadership, teacher training, and peace education. While formal awards are not specifically listed, his selection for international conferences, exchange programs, and educational fellowships demonstrates the high regard in which he is held by the academic community. He has represented Palestinian educators at international conferences in Spain, Japan, Turkey, and the United States, where he contributed to discussions on identity, educational reform, and non-violent conflict resolution. These participations were often by nomination or invitation, affirming his reputation as a respected leader in education. His achievements reflect a career dedicated to promoting understanding and academic excellence in challenging contexts. As a school principal and mentor, he continues to influence educational practice and policy at multiple levels, embodying a model of ethical leadership and civic responsibility.

Top Noted Publication

At present, there is no detailed record of published academic journal articles under Nader Neiroukh’s name; however, based on his extensive professional experience and academic involvement, he is well-positioned to publish on topics such as language education, school leadership, and peace pedagogy. His experience designing and implementing training programs, participating in international conferences, and leading school reforms offers valuable content for peer-reviewed publications. Potential areas of contribution include transformative learning in multilingual classrooms, teacher development frameworks in divided societies, and the integration of technology into EFL teaching. His ongoing doctoral work may also yield publishable research on education systems in conflict contexts. Once specific publications are available, they should be listed with journal names, publication years, and citation data to highlight scholarly impact. Nader’s professional and academic contributions provide a strong foundation for future publishing in national and international education journals.

Title: Impact of Virtual Reality Immersion in Biology Classes on Habits of Mind of East Jerusalem Municipality High School Students: Examining Mediating Roles of Self-Regulation, Flow Experience, and Motivation

  • Authors: Nader Neiroukh, Abedalkarim Ayyoub

  • Journal: Education Sciences

  • Year: 2025

Title: Organizational Communication Competence of Public Secondary School Principals Through Utilizing WhatsApp

  • Authors: N. Neiroukh, A.A. Ansari, R.A. Dalu, E. Khlaif, D. Barahmaeh, J. Zubeidi, B. Shtayeh, W. Daher

  • Journal: Frontiers in Education

  • Year: 2024

Conclusion

Mr. Nader Neiroukh is an accomplished educator with a distinguished career in school leadership, teacher training, and curriculum development. His efforts in promoting peace education and pedagogical innovation mark him as a dedicated and impactful figure in the field of education. However, in the context of the Best Researcher Award, which typically emphasizes research publications, scholarly output, and academic citations, his current profile aligns more closely with awards recognizing excellence in education, educational leadership, or lifelong service. While his contributions to educational practice are substantial, they would need to be supplemented by peer-reviewed research and scholarly publications to meet the core criteria of a research-specific recognition.